General Information of Drug (ID: DMKH32S)

Drug Name
Beta-methylmelatonin Drug Info
Synonyms beta-methylmelatonin; CHEMBL210147; SCHEMBL7055939
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
11630146
TTD Drug ID
DMKH32S

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ramelteon DM7IW9J Insomnia 7A00-7A0Z Approved [2]
Tasimelteon DMLOQ1V Insomnia 7A00-7A0Z Approved [3]
VLB-01 DMQGV5P Epilepsy 8A60-8A68 Phase 3 [4]
2-iodo-melatonin DMSEIUP Discovery agent N.A. Investigative [5]
N-(2,3,4,9-Tetrahydro-1H-carbazol-3-yl)-acetamide DMWC70I Discovery agent N.A. Investigative [6]
5-methoxycarbonylamino-N-acetyltryptamine DMCZSP3 Discovery agent N.A. Investigative [7]
N-(3-(2-ethoxy-5-methoxyphenyl)propyl)acetamide DMLWGPC Discovery agent N.A. Investigative [8]
UCM-454 DMSVJFG Discovery agent N.A. Investigative [9]
N-(3-(4-hydroxy-3-methoxyphenyl)propyl)acetamide DMILWPS Discovery agent N.A. Investigative [8]
N-(3-(5-methoxy-2-propoxyphenyl)propyl)acetamide DMHM0WI Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Melatonin DMKWFBT Depression 6A70-6A7Z Approved [10]
Ramelteon DM7IW9J Insomnia 7A00-7A0Z Approved [2]
Tasimelteon DMLOQ1V Insomnia 7A00-7A0Z Approved [3]
Neu-P11 DMIQDFW Alzheimer disease 8A20 Phase 2 [11]
LY-156735 DM5IX9M Anxiety disorder 6B00-6B0Z Phase 2 [12]
Agomelatine DMXYA5K Major depressive disorder 6A70.3 Withdrawn from market [13]
Luzindole DMXRJQV Sleep-wake disorder 7A00-7B2Z Terminated [14]
S-20928 DMQDWMJ Sleep-wake disorder 7A00-7B2Z Terminated [15]
GR-133347 DMNRJA0 Anxiety disorder 6B00-6B0Z Terminated [16]
GR-131663 DMKAGLV Anxiety disorder 6B00-6B0Z Terminated [17]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Melatonin receptor type 1A (MTNR1A) TT0WAIE MTR1A_HUMAN Inhibitor [1]
Melatonin receptor type 1B (MTNR1B) TT32JK8 MTR1B_HUMAN Inhibitor [1]

References

1 Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-me... J Med Chem. 2006 Jun 15;49(12):3509-19.
2 MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014 Apr 24;57(8):3161-85.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7393).
4 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
5 Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninergic binding sites MT(3). J Med Chem. 2002 Apr 25;45(9):1853-9.
6 Mapping the melatonin receptor. 2. synthesis and biological activity of indole derived melatonin analogues with restricted conformations of the C-3 amidoethane side chain, Bioorg. Med. Chem. Lett. 4(13):1559-1564 (1994).
7 Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3. Bioorg Med Chem. 2008 May 1;16(9):4954-62.
8 Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5.
9 2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists. J Med Chem. 2009 Feb 12;52(3):826-33.
10 The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway. J Neuroendocrinol. 2005 Mar;17(3):170-8.
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 288).
12 Melatonin and sleep in aging population. Exp Gerontol. 2005 Dec;40(12):911-25.
13 Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. Curr Top Med Chem. 2008;8(11):954-68.
14 Luzindole (N-0774): a novel melatonin receptor antagonist. J Pharmacol Exp Ther. 1988 Sep;246(3):902-10.
15 Effects of two melatonin analogues, S-20098 and S-20928, on melatonin receptors in the pars tuberalis of the rat. J Pineal Res. 1998 Oct;25(3):172-6.
16 US patent application no. 5,151,446, Substituted 2-amidotetralins as melatonin agonists and antagonists.
17 Novel non-indolic melatonin receptor agonists differentially entrain endogenous melatonin rhythm and increase its amplitude. Eur J Pharmacol. 1999 Oct 15;382(3):157-66.